Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1634 1653
This examiner grants 57% of resolved cases
Michael Angelo Riga is an examiner in Tech Center 1600 and Art Unit 1633. He has 70 resolved cases in his portfolio. His allowance rate is 57.1 percent. The data shows a very high interview lift of 61.2 percent. This suggests that interviews are an exceptionally powerful tool for moving toward an allowance with this examiner.
The median time to allowance is 1546 days. While the 70 resolved cases represent a smaller sample than some colleagues, the 61.2 percent lift is a standout metric. Applicants should prioritize interviews to leverage this 61.2 percent increase in allowance probability. The 1546 median days indicate a relatively long prosecution timeline.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18719340 | CONSTITUTIVE PRODUCTION OF MICROCINS TO TARGET ENTERIC BACTERIA | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 17612669 | MODIFIED VIRAL PARTICLES AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 16970216 | COMPOSITIONS AND METHODS FOR MEMBRANE PROTEIN DELIVERY | Final Rejection | FLAGSHIP PIONEERING INNOVATIONS V, INC. |
| 17309403 | AAV VIRAL VECTORS AND USES THEREOF | Final Rejection | NOVARTIS AG |
| 18258027 | IMPROVED PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR | Non-Final OA | Pfizer Inc. |
| 17998330 | COMPOSITIONS USEFUL IN TREATMENT OF KRABBE DISEASE | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18546746 | Transplantation of Liver Cells by Administration to the Biliary Tree of the Liver | Final Rejection | Cambridge Enterprise Limited |
| 17427648 | Liposomal Nanoparticle | Final Rejection | NewSouth Innovations Pty Limited |
| 17268635 | PHARMACEUTICAL COMPOSITION FOR TREATING CARTILAGE DAMAGE, COMPRISING NASAL SEPTUM CHONDROCYTES | Final Rejection | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17917198 | B7-H3 CHIMERIC ANTIGEN RECEPTORS | Final Rejection | St. Jude Children's Research Hospital, Inc. |
| 18843544 | WHARTON'S JELLY PREPARATION EFFECTIVE FOR PROMOTING BONE REGENERATION | Non-Final OA | NATIONAL YANG MING CHIAO TUNG UNIVERSITY |
| 17434513 | RECOMBINANT VECTORS COMPRISING ARYLSULFATASE A AND THEIR USES IN STEM CELL THERAPY FOR THE TREATMENT OF METACHROMATIC LEUKODYSTROPHY | Final Rejection | VERSITECH LIMITED |
| 18684082 | ENGINEERED ADAR-RECRUITING RNAS AND METHODS OF USE THEREOF | Non-Final OA | Edigene Therapeutics (Beijing) Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy